carboplatin & pegylated liposomal doxorubicin (pld) versus carboplatin & paclitaxel in...
TRANSCRIPT
![Page 1: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/1.jpg)
Carboplatin & Pegylated Liposomal Doxorubicin (PLD)
versus Carboplatin & Paclitaxel
in Relapsed, Platinum-sensitive
Ovarian CancerEric Pujade-Lauraineon behalf of all GCIG collaborators
CALYPSO trial
![Page 2: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/2.jpg)
Background
• Despite response to 1st-line treatment, relapse is eventual for most patients with advanced ovarian cancer (AOC)
• Choice of relapsed disease treatment is dependent on interval since prior platinum-based therapy – Relapse within 6 months: platinum-resistant
disease– Relapse over 6 months: platinum-sensitive
disease
• Carboplatin-paclitaxel is standard in platinum-sensitive disease
![Page 3: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/3.jpg)
Rationale for PLD-Carboplatin Doublet
• Due to risk of cumulative neuropathy and of hair loss, other carboplatin combinations have been explored
• Pegylated liposomal doxorubicin (PLD) is a rational choice for combined therapy– PLD outperformed topotecan in platinum-
sensitive population in large randomized trial (significant benefit in PFS and OS)1,2
– Phase II trial of PLD-carboplatin verified safety and efficacy3
1Gordon et al. J Clin Oncol. 2001;19:3312-3322; 2Gordon et al. ECCO 12. September 2003 (poster); 3Ferrero et al. Ann Oncol. 2007;18:263-268.
![Page 4: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/4.jpg)
CALYPSO Study Schema
Ovarian cancer in late relapse (> 6 months) after 1st- or 2nd-line
platinum-based therapy (previous taxane
required)
International, Intergroup, Open-label, Randomized Phase III Study
Stratification:
•Therapy-free interval (6-12 mo vs > 12 mo)
•Measurable disease (yes vs no)
•Center
RANDOMIZE
Experimental arm: CD
PLD 30 mg/m2 IV d 1
Carboplatin AUC 5 d 1
Control arm: CP
Paclitaxel 175 mg/m2 IV d 1
Carboplatin AUC 5 d 1
Q 28 days x 6 courses*
Q 21 days x 6 courses*
*or progression in patients with SD or PR
![Page 5: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/5.jpg)
Key Eligibility Criteria
• Age ≥ 18 years• ECOG performance status ≤ 2• Histologically proven diagnosis of cancer of
the ovary, fallopian tube, or extra-ovarian papillary serous tumors
• Disease progression > 6 months after 1st- or 2nd-line platinum-based therapy
• Previous taxane exposure• Measureable disease (RECIST criteria) or CA
125 assessable disease (GCIG criteria) or histologically proven diagnosis of relapse
![Page 6: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/6.jpg)
Endpoints. Statistical discussions
Primary endpoint• Progression-free survival (PFS)
Statistical considerations• Two-arm, parallel, NON-INFERIORITY study design• Statistical assumptions based on PFS from
ICON4/AGO-OVAR 2.2 trial1 • Declare non-inferior if HR one-side 95% CI <1.23
(CD:CP) for PFS• Power of 90% and one-sided confidence level of
95%• Number of events required : 745
1Parmar et al. Lancet. 2003;361:2099-2106.
![Page 7: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/7.jpg)
Endpoints
Secondary endpoints• Qualitative and quantitative toxicities• Quality of life (EORTC QLQ-C-30 version
3.0 and OV-28 questionnaire version 1.0)
• Overall survival (OS)
![Page 8: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/8.jpg)
Accrual
N=976
![Page 9: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/9.jpg)
CALYPSO Worldwide CollaborationAustria, Australia, Belgium, Canada, Denmark, Finland, France,
Germany, Italy, New Zealand, Saudi Arabia, Spain, Sweden, Switzerland, Turkey
![Page 10: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/10.jpg)
Accrual by Groups
49
76
317
227
71
17
22
137
60
![Page 11: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/11.jpg)
Baseline Characteristics (1)
CharacteristicCD (n=466) CP (n=508)
Number of patients (%)
Age, medianECOG performance status* 0 1 2Primary site of disease Ovarian
Papillary/Serous histology Initial FIGO stage* I/II III/IVNumber of previous lines One Two
60.5
286 (61)159 (34)13 (3)
415 (89)334 (72)
52 (11)401 (86)
408 (88) 58 (12)
61.0
317 (62)164 (32)15 (3)
451 (89)366 (72)
59 (12)427 (84)
421 (83) 87 (17)
* Missing values to attain 100%.
![Page 12: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/12.jpg)
Baseline Characteristics (2)
CharacteristicCD (n=466) CP (n=508)
Number of patients (%)
Prior taxane
Interval since prior therapy, median 6-12 months > 12 months
Measurable disease Yes No
Tumour size < 5 cm > 5 cm
Number of sites 1 > 1
462 (99)
162 (35)304 (65)
281(60)185 (39)
377(81) 89(19)
217(47)249 (53)
500 (99)
182 (36)326 (64)
321 (63)188 (37)
419 (82) 90 (18)
245(48)264(52)
![Page 13: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/13.jpg)
Treatment Exposure
CD (n=465)** CP (n=501)**
Total treatment duration, median wk* 21 16
Relative dose intensity % Carbo: 99PLD: 99
Carbo: 99Paclitaxel: 98
Patients with ≥ 6 cycles, n (%)* 395 (85) 392 (78)
Patients with ≥ 9 cycles, n (%) 36 (8) 36 (7)
* P< 0.001; ** Patients receiving at least one cycle
![Page 14: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/14.jpg)
Hematologic Toxicity
Toxicity, grade(gr)
CD (n=464)
CP (n=500) P Value
Number of patients (%)
Neutropenia, gr 3
gr 4
144 (31)
20 (4)
121 (24)
108 (22)
<0.01
Febrile neutropenia, gr 3-4
10 (2) 21 (4) NS
Infection, gr 3-4 11 (3) 14 (3) NS
Thrombocytopenia, gr 3-4 73 (16) 31 (6) <0.01
Bleeding, gr 3-4 3 (0.6) 0 (0) NS
Anemia, gr 3-4 37 (8) 27 (5) NS
NS=not significant.
![Page 15: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/15.jpg)
Selected Non-Hematologic Toxicities During Treatment
*P< 0.001
CD (n=466) CP (n=501)Grade 2 Grade3/4 Grade 2 Grade 3/4
Nausea/vomiting* 31% 4% 20% 4%
Constipation 19% 2% 20% 2%
Diarrhea 4% 2% 6% 2%
Arthralgia/myalgia* 4% 0% 18% 1%
Hand-foot syndrome* 11% 2% 2% 0%
Mucositis* 13% 2% 6% 1%
Fatigue 31% 7% 34% 7%
Cardiac disorders 2% 1% 3% 1%
![Page 16: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/16.jpg)
Selected Non-Hematologic Toxicities During Treatment
CD (n=466) CP (n=501)
Alopecia grade 2* 7% 84%
Alopecia
*P< 0.001
![Page 17: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/17.jpg)
Long-Lasting Toxicity
CD (n=466) CP (n=501)
Grade 2 Grade 3/5 Grade 2 Grade 3/5
Neuropathy* 4% 1% 24% 4%
Neuropathy score over time
EORTC OV28 – QoL Peripheral Neuropathy
*P< 0.001
![Page 18: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/18.jpg)
Early Treatment Discontinuation
ReasonCD (n=466) CP (n=501)
Number of patients (% of total)
Toxicity*
Patient/investigator choice
Progressive disease
Intercurrent disease
TOTAL*
27 (6)
16 (3)
26 (6)
1 (<1)
70 (15)
73 (15)
14 (3)
22 (4)
1 (<1)
110 (22)
* P< 0.001
![Page 19: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/19.jpg)
Carboplatin Hypersensitivity Reactions
CD (n=466) CP (n=501)
Grade 2 Grade 3/5 Grade 2 Grade 3/5
Hypersensitivity* 3% 2% 10% 9%
One drug stopped - 2%
Both drugs stopped 1% 4%
*P< 0.001
Protocol included EORTC guidelines for re-challenge after a hypersensitivity reaction to carboplatin
![Page 20: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/20.jpg)
Follow-up and Number of Events
• Median follow-up 22 months
• Number of events – Progressions or deaths 824 (85%)– Deaths 322 (33%)
![Page 21: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/21.jpg)
Progression-Free Survival (ITT)
CD CP
Median PFS, mo 11.3 9.4
HR (95% CI) 0.82 (0.72, 0.94)
Log-rank p-value (superiority) 0.005
P-value (non-inferiority) <0.001
![Page 22: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/22.jpg)
Symmetry of Tumor Assessments
![Page 23: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/23.jpg)
Sensitivity PFS analysis
![Page 24: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/24.jpg)
Multivariate Analysis of Baseline Predictive Factors on PFS
Significant predictors of PFS included
Baseline Factor NMultivariate Cox Regression Model
HR 95% CI P-value
Therapy-free interval
6-12 mo 342 1.00(0.48, 0.65) < 0.001
> 12 mo 617 0.56
Measurable Disease
No 362 1.00(1.27, 1.70) < 0.001
Yes 597 1.47
CA 125< 100 316 1.00
(1.52, 2.07) < 0.001≥100 643 1.77
Treatment arm
CP 499 1.00(0.71, 0.93) 0.003
CD 460 0.80
![Page 25: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/25.jpg)
Key findings• In patients with platinum-sensitive relapsing ovarian
cancer, the combination of PLD-carboplatin was not inferior in term of PFS to paclitaxel-carboplatin, and even was found significantly superior– 18% reduction in risk of recurrence (HR 0.82; P=0.005)
• Overall survival data immature, with only 322 deaths to date
• Paclitaxel-carboplatin associated with more severe toxicity (carboplatin hypersensitivity), alopecia, and long-lasting toxicity (neuropathy)
• Moderate reversible HFS, mucositis, and nausea/vomiting more frequent with PLD
![Page 26: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/26.jpg)
Conclusions
• Carboplatin-PLD demonstrated a superior therapeutic index (benefit/risk ratio) versus current standard, carboplatin-paclitaxel
• PLD- carboplatin offers an evidence-based option for patients with platinum-sensitive recurrent ovarian cancer
![Page 27: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Eric Pujade-Lauraine](https://reader036.vdocuments.mx/reader036/viewer/2022081418/56649ed35503460f94be3a19/html5/thumbnails/27.jpg)
Study Office B. Votan G. Elser G. Andersen M. Bacon J. Martin B. Volger A. Demeester J. Bryce R. Fossati N. Le Fur P. Schantl C. Jeppesen C. Goudreau K. Carlton J. Ulmer
Investigators
Acknowledgement Patients and their families, and …
E. Pujade -LauraineA. LortholaryF. JolyB.WeberL. GladieffA. FloquetR. LargillierM. FabbroA. Goupil R. DelvaE. GuardiolaF. PriouG.De RauglaudreD. Coeffic …
E. EisenhauerL. ElitP. SauthierJ. BentleyA. OzaH. ChalchalA. SugimotoM. HeywoodP. BessetteD. PopkinL. KaizerW. GotliebP. Walde …
G. KristensenJ. KaernR. SandveiJ. HerrstedtE. Aavall -LundqvistT. HogbergB. LundK. BomanH. HavsteenM. HansenJ. Maenpaa …
J. PfistererJ. SehouliA. Du BoisP. WimbergerB. SchmalfeldtJ. HuoberS. MahnerM. Gropp M. ThillK. BaumannA. BurgesA. StaehleR. KreienbergA. BelauM. Beckmann S. LoiblA. HasenburgG. EmonsW. AulitzkyL. Spaetling …
C. MarthA. ZeimetA. ReinthallerL. Angleitner -BoubenizekH. SchauerP. SeveldaE. Petru…
I. VergoteN. ReedK. Van EygenP. OttevangerM. Van der BurgA. Casado Herraez
S. PignataG. ScambiaR. SorioE. BredaA. De Matteis
A. FerreroN. ColomboN. DonadelloD. Gueli AllettiA. LissoniS. Siena
DSMBM. Gore
M. BradyM. Seiden
P. VaseyB. FitzharrisM. BuckT. BonaventuraM. VaughanM. DavyA. O’DonnellC. SteerM. QuinnM. Friedlander A. GoldrickF. Kirsten …
Supported by
Shering Plough InternationalS. Stopatschinskaja C. DohertyB. Winograd B. Hartley
K. Djazouli
K. RehmanM. FehrG. Tulunay
StatisticsV. GebskiC. Brown
Data ManagementH. Karsenty L. Bertel, B. VoulazS. Perrin
Web siteD. Pihan
Coordinating Centre
A. BonvoisinE. PlançonF. PinotN. Chiannilkulchai
GINECO AGO-OVAR NSGO NCIC-CTG ANZGOG AGO-Austria EORTC MITO MANGO
Safety OfficeS. Azouz
T. Tran